These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 24036443)

  • 1. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
    Samartzis EP; Labidi-Galy SI; Moschetta M; Uccello M; Kalaitzopoulos DR; Perez-Fidalgo JA; Boussios S
    Ann Transl Med; 2020 Dec; 8(24):1712. PubMed ID: 33490224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
    Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
    J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
    Driva TS; Schatz C; Haybaeck J
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
    Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
    Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
    Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
    Matsumoto T; Yamazaki M; Takahashi H; Kajita S; Suzuki E; Tsuruta T; Saegusa M
    Am J Clin Pathol; 2015 Sep; 144(3):452-63. PubMed ID: 26276776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
    Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
    Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.